Pulmonary hypertension in systemic sclerosis: Prevalence, incidence and predictive factors in a large multicentric italian cohort

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.76, 2013, Pages

  Iudici, Michele ^a   Codullo, Veronica ^b   Giuggioli, Dilia ^c   Riccieri, Valeria ^d   Cuomo, Giovanna ^a   Breda, Silvia ^b   Manfredi, Andreina ^c   Iannace, Nicoletta ^d   D'Alto, Michele ^a   Ghio, Stefano ^e   Rossi, Rosario ^c   Vizza, Carmine Dario ^d   Caporali, Roberto ^b   Valesini, Guido ^d   Ferri, Clodoveo ^c   Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Epidemiology; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; CAPILLARY BLOOD; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; ITALY; LUNG ARTERY PRESSURE; LUNG CAPACITY; LUNG DIFFUSION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PH MEASUREMENT; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; AGED; CHILD; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIAC CATHETERIZATION; CHILD; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; ITALY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84883747206     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. FERRI C, VALENTINI G, COZZI F et al.: Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
2. TAN FK: Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003; 29: 211-37.
3. ROMANO E, MANETTI M, GUIDUCCI S, CECCARELLI C, ALLANORE Y, MATUCCI-CERINIC M: The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S75-86.
4. NIKPOUR M, STEVENS WM, HERRICK AL, PROUDMAN SM: Epidemiology of systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 857-69.
5. Lo MONACO A, BRUSCHI M, La CORTE R, VOLPINARI S, TROTTA F: Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S10-4.
6. SCHMAJUK G, BUSH TM, BURKHAM J, KRISHNAN E, CHUNG L: Characterizing systemic sclerosis in Northern California: focus on Asian and Hispanicpatients. Clin Exp Rheumatol 2009; 27 (Suppl. 54): 22-5.
7. STEEN VD, ODDIS CV, CONTE CG, et al.: Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 1997; 40: 441-5.
8. MAYES MD, LACEY JV Jr, BEEBE-DIMMER J, et al.: Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 2246-55.
9. ARNETT FC, HOWARD RF, TAN F, et al.: Increased prevalence of systemic sclerosis inNative American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39: 1362-70.
10. Le GUERN V, MAHR A, MOUTHON L, et al.: Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004; 43: 1129-37.
11. ALAMANOS Y, TSIFETAKI N, VOULGARI PV, et al.: Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005; 34: 714-20.
12. SILMAN A, JANNINI S, SYMMONS D, BACON P: An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988; 27: 286-90.
13. TAMAKI T, MORI S, TAKEHARA K: Epidemiological study of patients with systemic sclerosis in Tokio. Arch Dermatol Res 1991; 283: 366-71.
14. CODULLO V, CAVAZZANA I, BONINO C, et al.: Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009; 36: 1464-9.
15. WELLS AU, STEEN V, VALENTINI G: Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 (Suppl. 3): 40-4.
16. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
17. HACHULLA E, GRESSIN V, GUILLEVIN L, et al.: Early detection of pulmonary arterial hypertension insystemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800.
18. PHUNG S, STRANGE G, CHUNG LP, et al.: Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-91.
19. MUKERJEE D, St. GEORGE D, COLEIRO B, et al.: Prevalence and outcome in systemic sclerosis associatedpulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93.
20. VONK MC, BROERS B, HEIJDRA YF, et al.: Systemic sclerosis and its pulmonary complications in TheNetherlands: an epidemiological study. Ann Rheum Dis 2009; 68: 961- 5.
21. AVOUAC J, AIRò P, MEUNE C, et al.: Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Ass ociation Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
23. LeROY EC, MEDSGER TA Jr: Criteria for the classification of early Systemic Sclerosis. J Rheumatol 2001; 28: 1573-6.
24. MEIER FMP, FROMMER KW, DINSER R, et al.: EUSTAR Co-authors. Update on the profile of the EUSTAR color: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012; 71: 1355-60.
25. D'ALTO M, GHIO S, D'ANDREA A, et al.: Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart 2011; 97: 112-7.
26. ALLANORE Y, MEUNE C: N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009; 27 (Suppl. 54): 59-63.
27. CHIGHIZOLA C, MERONI PL, SCHREIBER BE, et al.: Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clin Exp Rheumatol 2012; 30 (Suppl. 71): 81-5.
28. MUKERJEE D, St GEORGE D, KNIGHT C, et al.: Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6.
29. STEEN VD, GRAHAM G, CONTE C, et al.: Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-70.
30. DEUSCHLE, K. WEINERT, MO, BECKER, et al.: Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol 2011; 29 (Suppl. 65): S53-S59.
31. GALIÈ N, HOEPER MM, HUMBERT M, ESC Committee for Practice Guidelines (CPG ): Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
32. DENTON CP, HUMBERT M, RUBIN L, et al.: Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40.
33. KOWAL-BIELECKA O, AVOUAC J, PITTROW D, et al.; EPO SS Group: Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010; 37: 105-15.
34. MANDEL J, MARK EJ, HALES CA: Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162: 1964-73.
35. HACHULLA E: [Treatment of pulmonary arterial hypertension associated to systemic sclerosis]. Rev Med Intern 2004; 25: 195- 200.
36. HACHULLA E, de GROOTE P, GRESSIN V, et al.: The three-year incidence of pulmonary arterial hypertension associated with sistemi sclerosis in a multi center nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-9.
37. CHANG B, SCHACHNA L. WHITE B, et al.: Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269-74.
38. HACHULLA E, LAUNAY D, MOUTHON L, et al.: Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-9.
39. ALLANORE Y, BORDERIE D, AVOUAC J, et al.: High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284- 91.